Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CBIO vs CGEN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CGEN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)
CGEN Overall Winner
6-Pillar Tally: CBIO 1 – 5 CGEN
Matrix Metrics: CBIO 2 – 8 CGEN
As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Crescent Biopharma, Inc. (CBIO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CBIO carries a Unified Composite Score of 42.4/100 (HOLD) at $13.04 (N/M Forward P/E, -1228.4% operating margin), whereas CGEN carries 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin).
- Technical & Structure Timing Caution: CBIO is currently in a Breakdown options structure phase (RSI 45.6); meanwhile CGEN is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CBIO vs CGEN
CBIO
Crescent Biopharma, Inc. Common Stock
$13.04
-3.41% 1D
Market Cap
$564.1M
TTM Revenue
$15M
Forward P/E
N/M
Beta / 30D Vol
1.39β · 59% Vol
Unified Composite Score
42.4
HOLD
Tech 36.0
Fund 51.0
Flow 65.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
CGEN
Head-to-Head Winner
Compugen Ltd
$2.02
-0.98% 1D
Market Cap
$193.2M
TTM Revenue
$76M
Forward P/E
12.4x
Beta / 30D Vol
1.44β · 62% Vol
Unified Composite Score
47.1
HOLD
Tech 44.0
Fund 52.0
Flow 54.0
Mom 64.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (CBIO 1 – 5 CGEN)
1. Valuation Multiples
CGEN
Forward P/E
N/M
12.4x
Trailing P/E
N/M
5.2x
PEG Ratio
N/M
1.29x
EV / Revenue
26.3x
2.5x
2. Growth & Scale
CGEN
Revenue Growth (YoY)
+0.0%
+102.1%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$15M
$76M
Market Cap
$564.1M
$193.2M
3. Profitability & Quality
CGEN
Gross Margin
100.0%
86.2%
Operating Margin
-1228.4%
41.3%
Net Profit Margin
0.0%
47.9%
Return on Equity (ROE)
-160.8%
57.2%
4. Balance Sheet & Cash Flow
CGEN
Cash Generation (TTM)
-$154M
$32M EBITDA
Cash Flow Margin
N/A
41.9% EBITDA Mgn
Net Cash / Leverage
$170M Net Cash
$4.3M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
CBIO
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
127.8% (29th %ile)
89.7% (57th %ile)
Put/Call OI Skew
1.07x (Balanced)
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
CGEN
OpEx & R&D Intensity
N/A
44.9% of Rev ($34M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
High-Margin Pricing Power Moat
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CBIO (2) vs CGEN (8)| Institutional Metric | CBIO | CGEN | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $564.1M | $193.2M | CBIO | |
| Trailing P/E Ratio | N/M | 5.2x | CGEN | |
| Forward P/E Ratio | N/M | 12.4x | CGEN | |
| Revenue Growth (YoY) | +0.0% | +102.1% | CGEN | |
| Operating Margin (TTM) | -1228.4% | 41.3% | CGEN | |
| Net Profit Margin | 0.0% | 47.9% | CGEN | |
| Return on Equity (ROE) | -160.8% | 57.2% | CGEN | |
| 52-Week Range Position | 23% ($9–$27) | 33% ($1–$3) | CGEN | |
| Beta / 30D Volatility | 1.39β · 59% Vol | 1.44β · 62% Vol | CBIO | |
| Unified Institutional Score | 42.4 / 100 (HOLD) | 47.1 / 100 (HOLD) | CGEN | |
| Trailing 12M Revenue (USD) | $15M | $76M | Scale | |
| Gross Profit Margin (TTM) | 100.0% | 86.2% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 26.3x EV/Rev | 1.29x PEG · 2.5x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$154M ($170M Net Cash) | $32M EBITDA ($4.3M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CBIO +2.96 pp
3M Horizon
CGEN +7.5 pp
6M Horizon
CGEN +3.43 pp
1Y Horizon
CGEN +23.02 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CBIO Revenue | CGEN Revenue | CBIO Op. Margin | CGEN Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2016 | $0M | $0M | -172505.3% | -4576.3% | CGEN |
| FY2018 | N/A | $20M | N/A | -130.5% | CGEN |
| FY2020 | $10M | $0M | -506.8% | -1574.8% | CBIO |
| FY2021 | $0M | $10M | -5470.7% | -584.6% | CGEN |
| FY2022 | $0M | $10M | -63204.4% | -471.7% | CGEN |
| FY2023 | $0M | $30M | -392752.9% | -38.8% | CGEN |
| FY2024 | N/A | $30M | N/A | -53.4% | CGEN |
| FY2025 | $10M | $70M | -1407.5% | 43.1% | CGEN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CBIO
BREAKDOWN
Current IV
127.8%
IV Percentile
29th %ile
Put/Call OI Skew
1.07x (Balanced)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact CBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CGEN
BREAKDOWN
Current IV
89.7%
IV Percentile
57th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact CGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CBIO Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
CGEN Moat Profile
High-Margin Pricing Power Moat
Biotechnology Operator
OpEx & R&D Reinvestment
44.9% of Rev ($34M)
90D Engineering Disclosures
0 Published
Investor FAQ CBIO vs CGEN Key Questions & Quantitative Answers
As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Crescent Biopharma, Inc. (CBIO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CBIO carries a Unified Composite Score of 42.4/100 (HOLD) at $13.04 (N/M Forward P/E, -1228.4% operating margin), whereas CGEN carries 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin). Technical & Structure Timing Caution: CBIO is currently in a Breakdown options structure phase (RSI 45.6); meanwhile CGEN is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CGEN leads the Growth & Scale pillar: CBIO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $15M TTM revenue (100.0% gross margin, -1228.4% operating margin), compared with CGEN at +102.1% YoY revenue growth and +0.0% YoY earnings growth on $76M TTM revenue (86.2% gross margin, 41.3% operating margin). Across the 8-period historical trajectory (FY2016 to FY2025), CBIO cumulative revenue shifted +0.0% while CGEN shifted +250.0%. In operating R&D and SG&A reinvestment, CBIO deploys N/A (0 90-day corporate R&D disclosures) versus 44.9% of Rev ($34M) (0 disclosures) for CGEN.
CGEN screens cheaper on headline valuation multiples. CBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.3x EV/Revenue (unreported FCF margin), whereas CGEN trades at 12.4x Forward P/E, 5.2x Trailing P/E, 1.29x PEG, and 2.5x EV/Revenue (41.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CBIO (-160.8% ROE) versus CGEN (57.2% ROE) capital efficiency.
In options market volatility and institutional positioning, CBIO carries 127.8% implied volatility (29th %ile, Balanced (25th–60th %ile)), a 1.07x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.39β · 59% Vol realized risk). By comparison, CGEN carries 89.7% implied volatility (57th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 62% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CGEN vs CBIO · Reverse Pair
CBIO vs BNTC
· Sector Peer
CBIO vs AKTX
· Sector Peer
CGEN vs VCYT
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking